CG Oncology, Inc. Common stock (CGON) Financials

$39.82

south_east
-$0.04 (-0.09%)
Day's range
$39.15
Day's range
$40.27

CGON Income statement / Annual

Last year (2024), CG Oncology, Inc. Common stock's total revenue was $1.14 M, an increase of 458.33% from the previous year. In 2024, CG Oncology, Inc. Common stock's net income was -$88.04 M. See CG Oncology, Inc. Common stock,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Operating Revenue $1.14 M $204.00 K $191.00 K $10.36 M
Cost of Revenue $0.00 $0.00 $15.00 K $10.00 K
Gross Profit $1.14 M $204.00 K $176.00 K $10.35 M
Gross Profit Ratio 1 1 0.92 1
Research and Development Expenses $82.10 M $45.75 M $29.03 M $18.32 M
General & Administrative Expenses $33.70 M $9.90 M $6.41 M $4.65 M
Selling & Marketing Expenses $0.00 $0.00 -$15.00 K -$10.00 K
Selling, General & Administrative Expenses $33.70 M $9.90 M $6.39 M $4.64 M
Other Expenses $0.00 $0.00 $0.00 $0.00
Operating Expenses $115.81 M $55.65 M $35.42 M $22.95 M
Cost And Expenses $115.81 M $55.65 M $35.44 M $22.96 M
Interest Income $26.62 M $6.90 M $0.00 $0.00
Interest Expense $0.00 $0.00 $1.00 K $451.00 K
Depreciation & Amortization $32.00 K $17.00 K $15.00 K $10.00 K
EBITDA -$114.63 M -$55.43 M -$35.23 M -$12.38 M
EBITDA Ratio -100.64 -271.73 -184.46 -1.2
Operating Income Ratio -100.67 -271.81 -184.53 -1.22
Total Other Income/Expenses Net $26.63 M $6.84 M -$197.00 K -$233.00 K
Income Before Tax -$88.04 M -$48.61 M -$35.44 M -$12.84 M
Income Before Tax Ratio -77.29 -238.27 -185.57 -1.24
Income Tax Expense $0.00 $0.00 $0.00 $0.00
Net Income -$88.04 M -$48.61 M -$35.44 M -$12.84 M
Net Income Ratio -77.29 -238.27 -185.57 -1.24
EPS -1.41 -1.02 -0.66 -0.28
EPS Diluted -1.41 -1.02 -0.66 -0.28
Weighted Average Shares Out $62.50 M $66.64 M $66.64 M $66.64 M
Weighted Average Shares Out Diluted $62.50 M $66.64 M $66.64 M $66.64 M
Link